Lung Diseases Cies Search Engine [selected websites]

Loading

Blog Archive

Apr 22, 2008

Antisoma and Novartis : phase III lung cancer trial of ASA404

11 April 2008 – Cancer drug developer Antisoma plc (LSE: ASM; US OTC: ATSMY) announces that its partner Novartis has started the pivotal phase III trial of ASA404 combined with first-line chemotherapy in non-small cell lung cancer (NSCLC). The study, called ATTRACT-1, is designed to support applications for marketing authorisations in the US, Europe and other territories.

Its initiation triggers a USD 25 million milestone payment to Antisoma... Antisoma's Press Release - Novartis' Press Release -